SOPH Q1 2026: Net Dollar Retention Climbs to 117% as Platform Expansion Drives Upsell Momentum
Sophia Genetics delivered a robust Q1, marked by accelerating upsell within its installed base and a step-change in adoption of higher-value applications. The company’s AI-native genomic analysis platform is compounding network effects, with notable traction in both clinical and biopharma channels. Management’s reaffirmed outlook signals confidence in a back-half ramp, driven by onboarding of recent customer wins and further expansion into complex testing modalities.
Summary
- Platform Expansion Loop: Rapid adoption of new applications and higher-value tests is fueling organic growth.
- Operational Leverage Emerges: AI-driven efficiencies and targeted cost actions are supporting margin discipline.
- Visibility Into H2 Acceleration: Large customer go-lives and biopharma momentum set the stage for a back-half revenue surge.
Business Overview
Sophia Genetics operates a cloud-based, AI-powered platform (SOPHIA DDM) that enables hospitals, labs, and biopharma companies to analyze genomic data for precision medicine applications. The company generates revenue from clinical customers (hospitals and labs running genomic tests) and biopharma partners (drug development, companion diagnostics, and real-world evidence). Key segments include core genomic analysis, new applications (liquid biopsy, exomes), and biopharma services. Its network spans 537 institutions across 75 countries, processing over 2.5 million genomic profiles since inception.
Performance Analysis
Q1 revenue grew 22% year-over-year, with platform analysis volumes up 16% and strong contributions from both core clinical and biopharma channels. Notably, U.S. volumes expanded 28% while EMEA revenue outpaced the company average, underscoring global demand for decentralized testing. The company’s adjusted gross margin remained robust at 75.4%, reflecting the scalability of its cloud-native platform and positive mix shift toward higher-ASP applications such as liquid biopsy and enhanced exome tests.
Net dollar retention, a key metric for recurring software-like businesses, climbed to 117%—up from 103% a year ago—highlighting successful upsell and cross-sell into the existing customer base. Operating expenses rose, driven by currency headwinds and litigation costs, but underlying cost discipline remained intact. Cash burn increased due to bonus payouts and investment in expanded lab capacity, but the company ended the quarter with $65.4 million in cash and enhanced liquidity via an expanded credit facility.
- Regional Divergence: EMEA and APAC outperformed, while Latin America remained weak, prompting leadership changes and targeted turnaround plans.
- Application Mix Shift: Liquid biopsy volumes doubled year-over-year, and enhanced exome ramp is contributing to higher average selling prices (ASP).
- Biopharma Traction: New contracts with major pharma and biotech players are beginning to contribute, with further acceleration expected in H2 and 2027.
Despite foreign exchange drag and litigation costs, Sophia Genetics is demonstrating the operating leverage and recurring revenue characteristics of a high-quality platform business, with visibility into a stronger second half as new customers come online and higher-value applications scale.
Executive Commentary
"Our unique positioning and data set are enabling us to build for the future. We have been a technology company since day one, building real AI to solve the world's most difficult biological challenges. The market is coming to us, and I couldn't be more confident in our ability to deliver products for future growth."
Dr. Yergi Camblong, Co-founder & Chief Executive Officer
"We continue to make targeted investments in our platform to further optimize cloud compute and storage costs and expect gross margins to slightly expand beyond 2025 levels. These actions reinforce our conviction to grow revenue without increasing headcount."
George Cardoza, Chief Financial Officer
Strategic Positioning
1. Compounding Network Effects in Clinical Genomics
Sophia DDM’s growing network of 537 institutions is creating a data flywheel, where each new analysis enhances the platform’s AI models and clinical value. This virtuous loop is driving deeper adoption, as institutions increasingly consolidate testing and data management with trusted partners.
2. Expansion Into High-Value Applications
The rapid uptake of new applications—liquid biopsy, enhanced exome, and solid tumor testing—is shifting the revenue mix toward higher ASP and margin products. These offerings enable Sophia to expand wallet share within existing accounts, as evidenced by the 117% net dollar retention and multiple $1M+ annual contract value deals signed in Q1.
3. Biopharma Channel Momentum
Biopharma revenue is moving from episodic to recurring, as Sophia’s platform supports the full drug lifecycle from companion diagnostics to post-launch evidence generation. Strategic wins with AstraZeneca, Johnson & Johnson, and others, plus partnerships with Myriad Genetics and Adam Innovations, are establishing SOPH as a critical infrastructure provider for global precision medicine.
4. Operational Leverage Through AI-Driven Efficiency
Targeted cost actions and internal AI adoption are unlocking productivity gains, particularly in support and G&A functions. This enables reinvestment in growth initiatives while maintaining margin discipline, a key lever for approaching EBITDA breakeven by end of 2026.
5. Platform Scalability and Globalization
Investments in new lab capacity and cloud infrastructure are positioning Sophia to absorb volume growth and support increasingly complex, regulated applications across geographies. The company’s ability to onboard large U.S. and international accounts efficiently will be a determinant of sustained outperformance.
Key Considerations
This quarter’s results highlight Sophia Genetics’ transition from point-solution provider to platform orchestrator in precision medicine, with a business increasingly defined by recurring, high-margin revenue and global scale.
Key Considerations:
- Upsell Engine Strength: Net dollar retention at 117% signals strong customer expansion and validates the land-and-expand strategy.
- Biopharma Channel Evolution: Shift toward recurring, lifecycle-spanning contracts could drive margin and valuation uplift if sustained.
- Cost Discipline and AI Leverage: Early benefits from internal AI tools and focused cost actions are supporting margin expansion and reinvestment capacity.
- Regional Execution Variability: Latin America remains a drag, but leadership changes and product innovation may restore growth.
- Platform Stickiness: Low churn (<1%) and growing account density in key U.S. and European markets reinforce competitive moat.
Risks
Foreign exchange volatility, especially Swiss franc strength, continues to impact reported costs and could pressure margins if sustained. Ongoing patent litigation introduces expense and operational distraction, though recent court decisions have been favorable. Latin America’s persistent softness and the lumpy nature of biopharma revenue remain watchpoints. Execution on large customer onboardings and maintaining high ASP mix will be critical to meeting back-half weighted guidance.
Forward Outlook
For Q2 2026, Sophia Genetics guided to:
- Continued sequential revenue growth, with ramp from new customer go-lives and higher ASP applications
- Stable to slightly expanding gross margins, driven by operational efficiency and product mix
For full-year 2026, management reaffirmed guidance:
- Revenue of $92 to $94 million (20-22% growth)
- Adjusted EBITDA loss of $29 to $32 million, with breakeven targeted by end of 2026
Management highlighted several factors that will shape the outlook:
- Back-half weighted growth as 2025 signings ramp to revenue
- Biopharma momentum expected to accelerate further into 2027
Takeaways
Sophia Genetics is demonstrating the hallmarks of a scalable, recurring-revenue platform, with embedded growth drivers and operational discipline supporting a clear path to profitability.
- Land-and-Expand Maturity: Net dollar retention and new high-value applications are driving organic growth and margin mix improvement, with minimal incremental cost.
- Biopharma Inflection: Transition to recurring contracts and strategic partnerships signals a structural shift in channel economics and future revenue durability.
- Execution Watchpoints: Investors should monitor onboarding cadence for large accounts, ASP trajectory, and regional performance—especially in Latin America—for signals on sustained outperformance.
Conclusion
Sophia Genetics’ Q1 results underscore its evolution into a data-powered, AI-native platform business with global reach and expanding strategic relevance. If execution on customer expansion and biopharma acceleration holds, SOPH is positioned to deliver compounding growth and margin leverage into 2027 and beyond.
Industry Read-Through
Sophia’s results reinforce two major trends in precision medicine: the accelerating shift to decentralized, AI-enabled testing and the rising strategic value of real-world genomic data for both clinical and pharma stakeholders. The company’s ability to drive recurring revenue from both hospital networks and biopharma partners highlights the growing convergence of diagnostics and therapeutics. For the broader genomics and digital health sector, SOPH’s operating leverage and high net dollar retention set a new benchmark, while its regional execution challenges and exposure to FX volatility serve as cautionary notes for global healthtech peers. As platform models gain traction, winners will be defined by network effects, data flywheels, and the ability to monetize across the clinical-pharma continuum.